DNAprint Genomics (DNAG)

[IVRT]

DNAPrint Collaborates with NYU School of Medicine
SARASOTA, Fla., Dec 3, 2001 /PRNewswire via COMTEX/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) announced today that it has entered into a collaboration with the New York University School of Medicine to develop pharmacogenomic classifiers for organ transplant patients.
NYU's Mary Lea Johnson Richards Organ Transplantation Center will provide DNAPrint with informed consent qualified patient specimens and matching clinical data. DNAPrint will genetically screen the specimens for markers and/or marker sets that can be used to distinguish between drug responders and non-responders. To do this, the company will employ proprietary genotyping protocols, data resources (the PHENOME SNP database) and its powerful informatics platform.

The goal of the project is to identify pharmacogenomic classifiers that could be used to match renal transplantation patients with the optimal immunosuppressant for their genetic architecture. The project is expected to take about one year to complete, and the results are expected to extend to patients for a wide range of transplantation procedures.

About NYU's Transplant Program:

The Mary Lea Johnson Richards Organ Transplantation Center is one of the busiest and most successful transplant programs in the United States. The program offers transplantation of the liver, kidney and pancreas and performs about 150 transplants annually. Over 500 liver and 200 kidney transplants have been done since program inception and the programs graft and patient survival rates are consistently among the best in the country.

About DNAPrint genomics, Inc.:

DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.



Investor Relations Inquiries please contact:
Tim Wilkins
941/341-0136
[e-mail]
Or
Carrie Castillo
[e-mail]
941/366-3400

For Scientific Inquiries, please call:
Dr. Tony Frudakis
941/366-3400

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X19415882

SOURCE DNAPrint genomics, Inc.


CONTACT: Investor Relations: Tim Wilkins, [phone],
[e-mail], or Carrie Castillo, [phone],
[e-mail], or Scientific Inquiries: Dr. Tony Frudakis,
[phone], all for DNAPrint genomics Inc.

URL: http://www.dnaprint.com
http://www.prnewswire.com

Copyright (C) 2001 PR Newswire. All rights reserved.